• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两名2N型血管性血友病患者在止血治疗后及孕期血管性血友病因子的凝血因子VIII结合能力和凝血因子VIII促凝活性的变化

Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.

作者信息

Nishino M, Nishino S, Sugimoto M, Shibata M, Tsuji S, Yoshioka A

机构信息

Department of Pediatrics, Nara Prefectural Mimuro Hospital, Japan.

出版信息

Int J Hematol. 1996 Aug;64(2):127-34. doi: 10.1016/0925-5710(96)00470-7.

DOI:10.1016/0925-5710(96)00470-7
PMID:8854570
Abstract

The changes of the FVIII binding capacity of vWF after the infusion of FVIII/vWF concentrate was studied in two patients with type 2N vWD, and also during pregnancy in one of them. After infusion of FVIII or DDAVP to the patients, FVIII:C in plasma increased as expected, but it then decreased, with a markedly short half-life, of about 2 h, due to the defect in the FVIII binding capacity of vWF in plasma. However, after infusion of FVIII/vWF concentrate (40 U of FVIII:C/kg), FVIII:C increased, from 4-6 to 100-160 U/dl, more than the expected values, and decreased with the half-life expected. The FVIII binding capacity of vWF in plasma changed in parallel with the concentration of exogenous normal vWF, with a half-life of more than 24 h. During pregnancy, no increase of FVIII:C was observed, although vWF:Ag increased from 40 (before pregnancy) to 90 U/dl in plasma at 35th week of gestation. The FVIII binding capacity of vWF in plasma showed no increase during pregnancy. Accordingly, the administration of FVIII/vWF concentrate to the patient at delivery resulted in adequate hemostasis.

摘要

在两名2N型血管性血友病(vWD)患者中研究了输注FVIII/vWF浓缩物后vWF的FVIII结合能力变化,其中一名患者还在孕期进行了研究。给患者输注FVIII或去氨加压素(DDAVP)后,血浆中的FVIII:C如预期那样升高,但随后下降,半衰期明显较短,约为2小时,这是由于血浆中vWF的FVIII结合能力存在缺陷。然而,输注FVIII/vWF浓缩物(40 U FVIII:C/kg)后,FVIII:C从4 - 6 U/dl升高至100 - 160 U/dl,高于预期值,并以预期的半衰期下降。血浆中vWF的FVIII结合能力与外源性正常vWF的浓度平行变化,半衰期超过24小时。孕期未观察到FVIII:C升高,尽管在妊娠第35周时血浆中vWF:Ag从妊娠前的40 U/dl升高至90 U/dl。血浆中vWF的FVIII结合能力在孕期未升高。因此,在分娩时给该患者输注FVIII/vWF浓缩物可实现充分止血。

相似文献

1
Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.两名2N型血管性血友病患者在止血治疗后及孕期血管性血友病因子的凝血因子VIII结合能力和凝血因子VIII促凝活性的变化
Int J Hematol. 1996 Aug;64(2):127-34. doi: 10.1016/0925-5710(96)00470-7.
2
Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.2M型血管性血友病患者使用去氨加压素后及孕期因子VIII和血管性血友病因子的变化:维琴察的一项前瞻性研究,比较单一缺陷(R1205H)和双重缺陷(R1205H - M740I)的患者
J Thromb Haemost. 2006 Feb;4(2):357-60. doi: 10.1111/j.1538-7836.2006.01706.x.
3
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.静脉注射去氨加压素和因子VIII-血管性血友病因子浓缩物用于治疗和预防1型、2型和3型血管性血友病患者的出血。
Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399.
4
Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.2N型血管性血友病的诊断:一种测量因子VIII与血管性血友病因子结合的简化方法。
Am J Hematol. 1998 Aug;58(4):311-8. doi: 10.1002/(sici)1096-8652(199808)58:4<311::aid-ajh11>3.0.co;2-a.
5
Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.重度血管性血友病患者对去氨加压素的释放作用不敏感:这证明去氨加压素诱导的血浆因子VIII增加并非继发于血浆血管性血友病因子的增加。
Br J Haematol. 1994 Feb;86(2):333-7. doi: 10.1111/j.1365-2141.1994.tb04735.x.
6
Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group.
Br J Haematol. 1994 Dec;88(4):849-54. doi: 10.1111/j.1365-2141.1994.tb05127.x.
7
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.2型诺曼底隐性血管性血友病:轻度血友病和1型血管性血友病的可变表现。
Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8.
8
The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.去氨加压素对患有血管性血友病的犬血浆凝血因子VIII/血管性血友病因子活性的影响。
Can J Vet Res. 1987 Apr;51(2):189-93.
9
Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.血管性血友病因子与凝血因子VIII结合异常的血管性血友病隐性遗传的进一步证据。
Am J Hematol. 1992 May;40(1):20-7. doi: 10.1002/ajh.2830400105.
10
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.1型/2E型(2A亚型IIE)血管性血友病、1型维琴察型血管性血友病以及由血管性血友病因子基因的D3、D4、B1 - B3和C1 - C2结构域突变引起的轻型1型血管性血友病的实验室诊断。血管性血友病因子多聚体及血管性血友病因子前肽/抗原比值的作用。
Acta Haematol. 2009;121(2-3):128-38. doi: 10.1159/000214853. Epub 2009 Jun 8.

引用本文的文献

1
Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.利用基于微芯片的流室系统评估 2N 型血管性血友病患者的临床严重程度。
Int J Hematol. 2020 Mar;111(3):369-377. doi: 10.1007/s12185-019-02782-z. Epub 2019 Nov 18.
2
Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage.在一名自发性大腿出血患者中诊断出交叉反应物质阳性的甲型血友病。
Intern Med. 2017;56(13):1719-1723. doi: 10.2169/internalmedicine.56.7487. Epub 2017 Jul 1.